TABLE OF CONTENTS
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW 67
1.4 CURRENCY AND PRICING 69
1.5 LIMITATIONS 69
1.6 MARKETS COVERED 70
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 MARKET APPLICATION COVERAGE GRID 81
2.8 PRODUCT LIFELINE CURVE 82
2.9 DBMR MARKET POSITION GRID 83
2.10 VENDOR SHARE ANALYSIS 85
2.11 SECONDARY SOURCES 86
2.12 ASSUMPTIONS 86
3 EXECUTIVE SUMMARY 87
4 PREMIUM INSIGHTS 90
4.1 PORTERS FIVE FORCES 91
4.2 PESTEL ANALYSIS 92
4.3 INDUSTRY INSIGHTS 93
4.4 CONCLUSION 94
5 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 95
6 MARKET OVERVIEW 97
6.1 DRIVERS 99
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 99
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 99
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 100
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 100
6.2 RESTRAINTS 101
6.2.1 HIGH COST OF FISH TESTING 101
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 101
6.3 OPPORTUNITIES 102
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 102
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 102
6.4 CHALLENGES 103
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 103
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 103
7 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 104
7.1 OVERVIEW 105
7.2 CONSUMABLES 108
7.2.1 FISH PROBE 108
7.2.1.1 FISH PROBE, BY PROBE TYPE 109
7.2.1.1.1 CHROMOSOME FISH PROBE 109
7.2.1.1.2 SPLIT FISH PROBES 109
7.2.1.1.3 TRANSLOCATION FISH PROBES 109
7.2.1.1.4 SUBTELOMERE FISH PROBES 109
7.2.1.1.5 PRENATAL FISH PROBES 109
7.2.1.1.6 OTHERS PROBES 110
7.2.1.2 FISH PROBE, BY TECHNOLOGY 110
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 110
7.2.1.2.2 C-ISH 110
7.2.1.2.3 D-ISH 110
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 110
7.2.1.2.5 OTHERS 110
7.2.1.3 FISH PROBE, BY TYPE 111
7.2.1.3.1 RNA 111
7.2.1.3.1.1 MRNA 111
7.2.1.3.1.2 MIRNA 111
7.2.1.3.1.3 OTHERS 112
7.2.1.3.2 DNA 112
7.2.2 ACCESSORY KITS & REAGENTS 112
7.2.2.1 KITS 112
7.2.2.2 BUFFER 112
7.2.2.3 DYES 112
7.2.2.4 OTHERS 113
7.3 INSTRUMENT 113
7.3.1 STANDALONE 114
7.3.2 PORTABLE 114
7.3.3 HANDHELD 114
7.4 SOFTWARE 114
8 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 115
8.1 OVERVIEW 116
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 119
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 120
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 121
8.5 OTHERS 122
9 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 123
9.1 OVERVIEW 124
9.2 CANCER RESEARCH 127
9.2.1 CANCER RESEARCH, BY CANCER TYPE 128
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 128
9.2.1.1.1 BREAST CANCER 128
9.2.1.1.2 LUNG CANCER 128
9.2.1.1.3 MELANOMA 129
9.2.1.1.4 PROSTRATE CANCER 129
9.2.1.1.5 OVARIAN CANCER 129
9.2.1.1.6 OTHERS 129
9.2.1.2 HEMATOPOETIC MALIGNANCIES 129
9.2.1.2.1 LEUKEMIA 129
9.2.1.2.2 MULTIPLE MYELOMA 130
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 130
9.2.2 CANCER RESEARCH, BY PRODUCT 130
9.2.2.1 CONSUMABLES 130
9.2.2.2 INSTRUMENTS 130
9.2.2.3 SOFTWARE 130
9.3 GENETIC RESEARCH 131
9.3.1 CYTOGENETICS 132
9.3.2 CHROMOSOMAL ABNORMALITIES 132
9.3.3 OTHERS 132
9.4 INFECTIOUS DISEASE 132
9.4.1 CONSUMABLES 133
9.4.2 INSTRUMENTS 133
9.4.3 SOFTWARE 133
9.5 PERSONALIZED MEDICINE 133
9.6 OTHERS 134
10 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 135
10.1 OVERVIEW 136
10.2 RESEARCH 139
10.2.1 INSTRUMENTS 139
10.2.2 CONSUMABLES 140
10.2.3 SOFTWARE 140
10.3 CLINICAL 140
10.3.1 CONSUMABLES 141
10.3.2 INSTRUMENT 141
10.3.3 SOFTWARE 141
10.4 COMPANION DIAGNOSTIC 141
10.4.1 CONSUMABLES 142
10.4.2 INSTRUMENT 142
10.4.3 SOFTWARE 142
11 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 143
11.1 OVERVIEW 144
11.2 DIAGNOSTIC LABORATORIES 147
11.3 HOSPITALS & CLINICS 147
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 148
11.5 ACADEMIC & RESEARCH INSTITUTES 149
11.6 CONTRACT RESEARCH ORGANIZATIONS 149
11.7 OTHERS 150
12 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 151
12.1 OVERVIEW 152
12.2 RETAIL SALES 155
12.3 ONLINE SALES 155
12.4 DIRECT TENDER 156
12.5 OTHERS 157
13 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 158
13.1 NORTH AMERICA 159
13.1.1 U.S. 172
13.1.2 CANADA 180
13.1.3 MEXICO 188
14 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 196
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 196
15 SWOT ANALYSIS 197
16 COMPANY PROFILE 198
16.1 MERCK KGAA 198
16.1.1 COMPANY SNAPSHOT 198
16.1.2 REVENUE ANALYSIS 198
16.1.3 COMPANY SHARE ANALYSIS 199
16.1.4 PRODUCT PORTFOLIO 199
16.1.5 RECENT DEVELOPMENT 199
16.2 ABBOTT 200
16.2.1 COMPANY SNAPSHOT 200
16.2.2 REVENUE ANALYSIS 200
16.2.3 COMPANY SHARE ANALYSIS 201
16.2.4 PRODUCT PORTFOLIO 201
16.2.5 RECENT DEVELOPMENT 202
16.3 AGILENT TECHNOLOGIES, INC. 203
16.3.1 COMPANY SNAPSHOT 203
16.3.2 REVENUE ANALYSIS 203
16.3.3 COMPANY SHARE ANALYSIS 204
16.3.4 PRODUCT PORTFOLIO 204
16.3.5 RECENT DEVELOPMENT 204
16.4 F. HOFFMANN-LA ROCHE LTD. 205
16.4.1 COMPANY SNAPSHOT 205
16.4.2 REVENUE ANALYSIS 205
16.4.3 COMPANY SHARE ANALYSIS 206
16.4.4 PRODUCT PORTFOLIO 206
16.4.5 RECENT DEVELOPMENT 206
16.5 THERMO FISCHER SCIENTIFIC INC. 207
16.5.1 COMPANY SNAPSHOT 207
16.5.2 REVENUE ANALYSIS 207
16.5.3 COMPANY SHARE ANALYSIS 208
16.5.4 PRODUCT PORTFOLIO 208
16.5.5 RECENT DEVELOPMENT 209
16.6 ABCAM PLC. 210
16.6.1 COMPANY SNAPSHOT 210
16.6.2 REVENUE ANALYSIS 210
16.6.3 COMPANY SHARE ANALYSIS 211
16.6.4 PRODUCT PORTFOLIO 211
16.6.5 RECENT DEVELOPMENTS 211
16.7 ABNOVA CORPORATION 213
16.7.1 COMPANY SNAPSHOT 213
16.7.2 PRODUCT PORTFOLIO 213
16.7.3 RECENT DEVELOPMENT 213
16.8 BIO SB 214
16.8.1 COMPANY SNAPSHOT 214
16.8.2 PRODUCT PORTFOLIO 214
16.8.3 RECENT DEVELOPMENT 214
16.9 BIOCARE MEDICAL, LLC 215
16.9.1 COMPANY SNAPSHOT 215
16.9.2 PRODUCT PORTFOLIO 215
16.9.3 RECENT DEVELOPMENT 216
16.10 BIOCAT GMBH 217
16.10.1 COMPANY SNAPSHOT 217
16.10.2 PRODUCT PORTFOLIO 217
16.10.3 RECENT DEVELOPMENT 218
16.11 BIODOT 219
16.11.1 COMPANY SNAPSHOT 219
16.11.2 PRODUCT PORTFOLIO 219
16.11.3 RECENT DEVELOPMENT 219
16.12 BIOGENEX 220
16.12.1 COMPANY SNAPSHOT 220
16.12.2 PRODUCT PORTFOLIO 220
16.12.3 RECENT DEVELOPMENT 220
16.13 BIO-TECHNE 221
16.13.1 COMPANY SNAPSHOT 221
16.13.2 REVENUE ANALYSIS 221
16.13.3 COMPANY SHARE ANALYSIS 222
16.13.4 PRODUCT PORTFOLIO 222
16.13.5 RECENT DEVELOPMENT 222
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH 223
16.14.1 COMPANY SNAPSHOT 223
16.14.2 PRODUCT PORTFOLIO 223
16.14.3 RECENT DEVELOPMENT 224
16.15 EXCILONE 225
16.15.1 COMPANY SNAPSHOT 225
16.15.2 PRODUCT PORTFOLIO 225
16.15.3 RECENT DEVELOPMENT 225
16.16 GENEMED BIOTECHNOLOGIES, INC. 226
16.16.1 COMPANY SNAPSHOT 226
16.16.2 PRODUCT PORTFOLIO 226
16.16.3 RECENT DEVELOPMENT 226
16.17 KANEKA EUROGENTEC S.A. 227
16.17.1 COMPANY SNAPSHOT 227
16.17.2 PRODUCT PORTFOLIO 227
16.17.3 RECENT DEVELOPMENT 227
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH 228
16.18.1 COMPANY SNAPSHOT 228
16.18.2 PRODUCT PORTFOLIO 228
16.18.3 RECENT DEVELOPMENT 228
16.19 METASYSTEMS 229
16.19.1 COMPANY SNAPSHOT 229
16.19.2 PRODUCT PORTFOLIO 229
16.19.3 RECENT DEVELOPMENT 229
16.20 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION) 230
16.20.1 COMPANY SNAPSHOT 230
16.20.2 REVENUE ANALYSIS 230
16.20.3 PRODUCT PORTFOLIO 231
16.20.4 RECENT DEVELOPMENT 231
16.21 ZYTOMED SYSTEMS GMBH 232
16.21.1 COMPANY SNAPSHOT 232
16.21.2 PRODUCT PORTFOLIO 232
16.21.3 RECENT DEVELOPMENT 232
17 QUESTIONNAIRE 233
18 RELATED REPORTS 237

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.